Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Lung Cancer

Volumn 64, Issue 1, 2009, Pages 60-65

  Eisen, Tim ^a,g   Thatcher, Nick ^b   Leyvraz, Serge ^c   Miller Jr , Wilson H ^d   Couture, Felix ^e   Lorigan, Paul ^b   Lüthi, François ^c   Small, David ^d   Tanovic, Adnan ^f   O'Brien, Mary ^g  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d MCGILL UNIVERSITY   (Canada)

^e Hotel Dieu de Levis Hospital   (Canada)

^f PHARMAMAR S A   (Spain)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Lung; Plitidepsin; SCLC; Second line

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; PLITIDEPSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SOLID TUMOR; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT REFUSAL; TREATMENT RESPONSE; VOMITING;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DEPSIPEPTIDES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SKIN NEOPLASMS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 61749103952     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.06.017     Document Type: Article

References (33)

1. Page NC, Read WL, Tierney RM. The epidemiology of small cell lung carcinoma. Proc ASCO 2002:305a.
2. Kurup A., and Hanna N.H. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 52 2 (2004) 117-126
3. Perry M.C., Eaton W.L., Propert K.J., Ware J.H., Zimmer B., Chahinian A.P., et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316 15 (1987) 912-918
4. Simon R.S., and Wagner H. Small cell lung cancer. Chest 123 (2003) 259S-271S
5. Rosti G., Carminati O., Monti M., Tamberi S., and Marangolo M. Chemotherapy advances in small cell lung cancer. Ann Oncol 17 Suppl 5 (2006) 99-102
6. Ebi N., Kubota K., Nishiwaki Y., Hojo F., Matsumoto T., Kakinuma R., et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 27 3 (1997) 166-169
7. Chute J.P., Kelley M.J., and Venzon D. Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer. Chest 110 1 (1996) 165-171
8. Greco F.A. Treatment options for patients with relapsed small cell lung cancer. Lung Cancer 9 Suppl 1 (1993) s85-s89
9. Garcia-Fernandez L.F., Losada A., Alcaide V., Alvarez A.M., Cuadrado A., Gonzalez L., et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 21 49 (2002) 7533-7544
10. Suarez Y., Gonzalez-Santiago L., Zarich N., Davalos A., Aranda J.F., Alonso M.A., et al. Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content. Mol Pharmacol 70 5 (2006) 1654-1663
11. Cuadrado A., Gonzalez L., Suarez Y., Martinez T., and Munoz A. JNK activation is critical for aplidin-induced apoptosis. Oncogene 23 27 (2004) 4673-4680
12. ®. AACR Annual Meeting; 2007 April 14-18 (abstract number 5580). Los Angeles, CA (2007)
13. Cuadrado A., Garcia-Fernandez L.F., Gonzalez L., Suarez Y., Losada A., Alcaide V., et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 278 1 (2003) 241-250
14. Gonzalez-Santiago L., Suarez Y., Zarich N., Muñoz-Alonso M.J., Cuadrado A., Martinez T., et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 13 11 (2006) 1968-1981
15. Broggini M., Marchini S.V., Galliera E., Borsotti P., Taraboletti G., Erba E., et al. a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17 1 (2003) 52-59
16. Straight A.M., Oakley K., Moores R., Bauer A.J., Patel A., Tuttle R.M., et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 57 1 (2006) 7-14
17. Anthoney A, Paz-Ares L, Twelves C. Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24 hour, weekly schedule. Proc Am Soc Clin Oncol 2000;Abstract 734.
18. Bowman A, Izquierdo MA, Jodrell D, Martinez M, Cicchella B, Jimeno J. Phase I clinical and pharmacokinetic (PK) study of the marine compound aplidin (APL), administered as a 1 hour weekly infusion. Proc Am Soc Clin Oncol 2001;Abstract 476.
19. Faivre S., Chieze S., Delbaldo C., Ady-Vago N., Guzman C., Lopez-Lazaro L., et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 23 31 (2005) 7871-7880
20. Jimeno J., Lopez-Martin J.A., Ruiz-Casado A., Izquierdo M.A., Scheuer P.J., and Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 15 4 (2004) 321-329
21. Ciruelos EM, Twelves C, Dominguez MJ, Mckay H, Anthony A, Castellanos D. Phase I clinical and pharmacokinetic study of the marine compound aplidin (APL) administered as a 3 hour infusion every 2 weeks. Proc Am Soc Clin Oncol 2002;Abstract 422.
22. Maroun J.A., Belanger K., Seymour L., Matthews S., Roach J., Dionne J., et al. I study of Aplidine in a daily ×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 17 (2006) 1371-1378
23. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al., Somerfield MRftASoCOGFEP. Somerfield MRftASoCOGFEP. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18 20 (2000) 3558-3585
24. Gralla R., Osoba D., Kris M., Kirkbride P., Hesketh P.J., Chinnery L.W., et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17 (1999) 2971-2994
25. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
26. National Cancer Institute Common Toxicity Criteria. Version 2.0, June 1, 1999. Available at: http://ctep.info.nih.gov. Accessed January 20, 2005.
27. Simon R. Optimal two-stage designs for clinical trials. Control Clin Trials 10 (1989) 1-10
28. Tiseo M., and Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2 8 (2007) 764-772
29. Dongiovanni V., Buffoni L., Berruti A., Dongiovanni D., Grillo R., Barone C., et al. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 58 2 (2006) 203-209
30. MacCallum C., and Gillenwater H.H. Second-line treatment of small-cell lung cancer. Curr Oncol Rep 8 4 (2006) 258-264
31. O'Brien M., Eckardt J., and Ramlau R. Recent advances with topotecan in the treatment of lung cancer. Oncologist 12 10 (2007) 1194-1204
32. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 2 (1999) 658-667
33. Micke P., Faldum A., Metz T., Beeh K.M., Bittinger F., Hengstler J.G., et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease?. Lung Cancer 37 3 (2002) 271-276